Idiopathic Inflammatory Myopathies

SAN DIEGO — Clinical trials exploring intravenous immunoglobulin and Janus kinase inhibition headline a robust pipeline for idiopathic inflammatory myopathies, according to a speaker at the 2023 Congress of Clinical Rheumatology West.

Specialized physical therapy may prevent deterioration and improve sexual function in female patients with systemic sclerosis and idiopathic inflammatory myopathies, according to data presented at the EULAR 2022 Congress.

The mean annual direct and indirect costs related to idiopathic inflammatory myopathies are three to five times higher than in the general population, and begin increasing 2 years before diagnosis, according to data from a Swedish registry.